
David Sinclair launches first oral reprogramming bid, after Life Biosciences dosed a glaucoma patient
Reprogramming is surging again, but the science, safety, and funding bets are still one big question mark.
By Hessa Al-Faleh·· 4 min
1 briefing · “glaucoma”

Reprogramming is surging again, but the science, safety, and funding bets are still one big question mark.